# Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)

> **NCT04678453** · PHASE1 · TERMINATED · sponsor: **NKGen Biotech, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Alzheimer Disease
- Neuro-Degenerative Disease

## Interventions

- **BIOLOGICAL:** SNK01

## Key facts

- **NCT ID:** NCT04678453
- **Lead sponsor:** NKGen Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-06
- **Primary completion:** 2023-08-16
- **Final completion:** 2024-01-31
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** The study was terminated after completing the dose escalation portion of the study. The expansion cohort was not initiated to conduct a global trial based on the approved US IND using a new manufacturing process.
- **Last updated:** 2024-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04678453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04678453, "Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04678453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*